Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1162479 | 0.79 | VHL (0.50) | VHLMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL19772267 | 0.78 | RAB9A (0.40) | VHLALDH1A1RAB9AHPGDNOS3 | |
| SCHEMBL4098437 | 0.78 | NOS3 (0.43) | RAB9AHPGDNOS3NOS1NOS2 | |
| SCHEMBL14021949 | 0.78 | RAB9A (0.36) | RAB9AHPGDNOS3NOS1NOS2 | |
| SCHEMBL17471237 | 0.78 | EPHX2 (0.40) | MEN1KMT2AALDH1A1RAB9AHPGD | |
| SCHEMBL9705676 | 0.78 | VHL (0.43) | VHLMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL805506 | 0.77 | — | — | |
| SCHEMBL9705933 | 0.77 | VHL (0.42) | VHLMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL2536820 | 0.76 | HPGD (0.35) | RAB9AHPGDNOS3NOS1NOS2 | |
| SCHEMBL1233711 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020247546-A1 | ADENOSINE ANALOGS FOR THE TREATMENT OF DISEASE | BIOINTERVENE, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-10035819-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-07-31 | — | — | US | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170226154-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-8633206-B2 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8058447-B2 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-15 | — | — | US | disclosed |
| EP-1926727-B1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7989633-B2 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1926727-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | Bayer HealthCare AG (DE) | 2008-06-04 | — | — | EP | disclosed |
| EP-1910329-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE | Bayer HealthCare AG (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007025604-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007009670-A1 | 4-CHROMENONYL-1,4-DIHYDROPYRIDINECARBONITRILES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2005087740-A1 | FLUORENONE 1, 4,-DIHYDROPYRIDIN DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-09-22 | — | — | WO | disclosed |
| EP-0192931-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLES | FIRMENICH SA (CH) | 1988-09-07 | — | — | EP | disclosed |
| US-4670109-A | ANODIC OXIDATION OF ALPHA-BETA UNSATURATED OXIMES | FIRMENICH SA (CH) | 1987-06-02 | — | — | US | disclosed |
| EP-0192931-A1 | Process for the preparation of isoxazoles | FIRMENICH SA (CH) | 1986-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022484-A1 | 4-Chromenonyl-1,4-dihydropyridines and their use | RYR1, RYR2, CACNA1S | VHL 111/4885MEN1 2250/4885KMT2A 3652/4885 |
| US-20090214675-A1 | 4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof | RYR1, TNNI3, RYR2 | VHL 78/4885MEN1 1937/4885KMT2A 3690/4885 |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | VHL 375/4885MEN1 4454/4885KMT2A 2760/4885 |
| US-20170226154-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | VHL 1745/4885MEN1 4675/4885KMT2A 3095/4885 |
| US-10035819-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | VHL 2006/4885MEN1 4525/4885KMT2A 3234/4885 |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | VHL 429/4885MEN1 4457/4885KMT2A 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.